BRAF Gene Mutation Clinical Trial
Official title:
A Pilot Study of Dabrafenib and Trametinib for Patients With BRAF Mutated Ameloblastoma
This pilot clinical trial studies dabrafenib and trametinib in treating patients with ameloblastoma and a specific mutation (change) in the BRAF gene. Dabrafenib and trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
PRIMARY OBJECTIVES: I. To observe the response rate of ameloblastoma to dabrafenib and trametinib at 6 weeks. SECONDARY OBJECTIVES: I. Feasibility and safety in this patient population. II. Response will be assessed pathologically. III. Two main histologic assays for treatment response will be used: tumor necrosis and phosphorylated-mitogen-activated protein kinase kinase 1 (MEK), phosphorylated-extracellular signal-regulated kinase (ERK), and Ki-67 levels as measured by immunohistochemistry. OUTLINE: Patients receive dabrafenib orally (PO) twice daily (BID) every 12 hours and trametinib 2 mg daily PO for 6 weeks in the absence of disease progression or unacceptable toxicity. Patients whose disease is judged to be not amenable to resection will continue dabrafenib and trametinib indefinitely as long as there has not been tumor progression. After completion of study treatment, patients are followed up for at least 4 weeks. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06287463 -
Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03049618 -
Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475
|
Phase 2 | |
| Active, not recruiting |
NCT03088176 -
Combining Talimogene Laherparepvec With BRAF and MEK Inhibitors in BRAF Mutated Advanced Melanoma
|
Phase 1 | |
| Withdrawn |
NCT03972046 -
Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Melanoma
|
Phase 2 | |
| Recruiting |
NCT04903119 -
Nilotinib Plus Dabrafenib/Trametinib in Metastatic Melanoma
|
Phase 1 | |
| Completed |
NCT03750175 -
OPTImal PALliative Anti-epidermal Growth Factor Receptor Treatment in Metastatic Colorectal Cancer -
|
||
| Terminated |
NCT04488003 -
Study of Ulixertinib for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations
|
Phase 2 | |
| Recruiting |
NCT04238624 -
Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer
|
Phase 2 | |
| Completed |
NCT01531361 -
Vemurafenib With Sorafenib Tosylate or Crizotinib in Treating Patients With Advanced Malignancies With BRAF Mutations
|
Phase 1 | |
| Recruiting |
NCT06270082 -
Study of IK-595 in RAS- or RAF-altered Advanced Tumors
|
Phase 1 | |
| Completed |
NCT03784378 -
Continued Access to RXDX-105
|
Phase 1 | |
| Terminated |
NCT01907802 -
Dabrafenib in Treating Patients With Solid Tumors and Kidney or Liver Dysfunction
|
Phase 1 | |
| Active, not recruiting |
NCT02925689 -
Dabrafenib in Treating Patients With Solid Tumors and Kidney or Liver Dysfunction
|
Phase 1 | |
| Completed |
NCT01700582 -
French National Observatory of the Patients With Non-small Cell Lung (NSCLC) and Molecular Testings
|
||
| Recruiting |
NCT05786924 -
A Study of BDTX-4933 in Patients With KRAS, BRAF and Select RAS/MAPK Mutation-Positive Cancers
|
Phase 1 | |
| Recruiting |
NCT06449989 -
Comparison of Molecular-Genetic Concordance of the Primary Tumor and Brain Metastases of Colorectal Cancer
|
||
| Available |
NCT04566393 -
Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies
|